South African Scientists Decode How Cancer Rewires MUC1 Sugar Coating to Evade the Immune System
Key Insights
University of Cape Town researchers published in Nature Communications the molecular mechanism by which cancer alters MUC1 (search) glycosylation, transforming a protective protein into a tumor-promoting shield.
The team discovered that in tumor cells, sugar-chain-building enzymes relocate from the Golgi apparatus to the endoplasmic reticulum, bypassing normal cellular checks and creating aberrant Tn and sTn antigens.
Using quantum chemistry simulations, scientists pinpointed the T13 site on MUC1 (search) as the preferred location for cancer-driven sugar alterations, driving the increase in sTn antigen seen in malignant tumors.
A research team led by the University of Cape Town (UCT)'s Scientific Computing Research Unit has decoded the molecular assembly line reorganization that allows cancer cells to "redecorate" the MUC1 (search) protein, turning it from a protective sentinel into a cloak of invisibility that shields tumors from the immune system. The findings, recently published in Nature Communications, represent what the researchers describe as "a major leap forward in our ability to decode one of cancer's most effective survival strategies."
In healthy cells, the Mucin-1 (MUC1 (search)) protein sits on the epithelial cell wall draped in a complex armor of long sugar chains, where it serves as a physical shield against bacteria, viruses, and toxins while communicating with the immune system. But in cancer, this guardian undergoes a malignant makeover: the sugar molecules are cut short or altered, creating aberrant structures known as the Tn and sialyl-Tn (sTn) antigens that tag tumor cells and actively suppress immune responses.
Relocating the enzymatic factory
The UCT team developed a novel in vitro synthetic biology approach to recreate the transition from a healthy sugar coating to a cancerous one. In normal cells, the enzymes that build long sugar chains reside in the Golgi apparatus, the cell's packaging and delivery center. The researchers discovered that in tumor cells, these enzymes are relocated to the endoplasmic reticulum — the cell's "factory floor."
This relocation proves decisive. In the endoplasmic reticulum, the enzymes are no longer subject to the usual cellular checks and balances, allowing them to take over sugar sites on the MUC1 (search) protein and create the foundation for the cancerous Tn antigen.
Pinpointing the T13 site with quantum chemistry
To deepen their understanding, the researchers employed quantum chemistry, simulating the behavior of atoms and molecules at the most fundamental level. This approach identified a specific location on the MUC1 (search) protein — the T13 site — that cancer enzymes preferentially target. This specific interaction drives the massive increase in the sTn antigen observed in malignant tumors.
"Understanding the location and nature of the MUC1 (search) sugars that prevent the immune system from detecting tumours provides the foundation for our laboratory and others in the field to develop cancer vaccines, biomarkers and therapeutics," the researchers stated.
From test tube to patient
The discovery has immediate translational implications. Because MUC1 (search) is found across numerous cancer types — including breast, colon, and lung cancers — the US National Cancer Institute has ranked it as the most accessible target for therapeutic intervention.
The next phase of the research, detailed in a recent paper in Glycobiology, involves building a sophisticated systems biology computational model that connects changes in the MUC1 (search) sugar coating to immune cell behavior. The team found that when these cancerous sugars interact with macrophages, they trigger the release of specific signals that instruct the tumor to grow and spread.
The researchers are now refining these details across different cancer types, comparing common forms of breast cancer (search) with more aggressive, currently untreatable variants to determine whether the "sugar code" differs between them. By using atomic-level data to build computer models of the entire biological system, the team aims to identify new drugs capable of blocking these tumor-promoting signals.
The ultimate goal is precision medicine: treatments that can strip away cancer's sugar shield, allowing the patient's own immune system to finally see and destroy the tumor.